— Medical Doctor
Dr Natalia Sutiman is a medical doctor whose approach to care is shaped by her background in both pharmacy and clinical research. She earned her Doctor of Medicine from Duke-NUS Medical School. Prior to that, she worked as a pharmacist at Tan Tock Seng Hospital and in Clinical Pharmacology research with SingHealth, where she contributed to clinical trials, therapeutic drug monitoring and genomics studies.
Her medical training spans rotations across multiple disciplines at Singapore's major hospitals, including Internal Medicine and Emergency Medicine at Singapore General Hospital, Paediatric Medicine at KK Women's and Children's Hospital, and primary care at SingHealth Polyclinics. This breadth of training equips her to care for patients across all ages and a wide range of conditions.
While her experience spans clinical medicine, pharmacy and research, Dr Natalia has always been drawn to the human aspects of patient care. She places great importance on listening with intention, communicating medical decisions with clarity, and working closely with her patients to support their long-term health.
Proactive health strategies and screening to identify and address health risks early.
Management of both immediate medical concerns and long-term health conditions.
Careful evaluation of complex or evolving symptoms to guide a clearer diagnosis.
Comprehensive healthcare addressing the unique needs of women at every stage of life.
A science-based approach shaped by published medical research and clinical experience.
"I believe that good care starts with genuinely understanding each patient's concerns and circumstances. Having trained in both research and clinical medicine, I try to ensure that every treatment plan is grounded in evidence and suited to the individual."
Dr Natalia Sutiman
"I believe that good care starts with genuinely understanding each patient's concerns and circumstances. Having trained in both research and clinical medicine, I try to ensure that every treatment plan is grounded in evidence and suited to the individual."
Dr Natalia Sutiman
Before entering clinical practice, Dr Natalia built a research career spanning more than 400 citations in peer-reviewed journals. Her work in pharmacogenomics explored how genetic differences in Asian populations influence medication response, particularly across cancer and inflammatory disease treatments.
| Published Works | |
|---|---|
Identifying the thresholds of C-reactive protein, procalcitonin, and interleukin-6 among children ≤ 36 months' old with fever without source at risk of serious bacterial infections: A systematic review and meta-analysis | |
Asthma exacerbation in children — Is there pneumonia? | |
Protocol for the diagnostic performance of C reactive protein, procalcitonin and interleukin-6 for serious bacterial infections among children ≤ 36 months old presenting with fever without source: A systematic review and meta-analysis | |
Delayed presentation is associated with serious bacterial infections among febrile infants: A prospective cohort study | |
Cross-ancestry genome-wide association study defines the extended CYP2D6 locus as the principal genetic determinant of endoxifen plasma concentrations | |
Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13 | |
Validation and comparison of the PECARN rule, Step-by-Step approach and Lab-score for predicting serious and invasive bacterial infections in young febrile infants | |
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects | |
Survival outcomes of paediatric patients with acute myeloid leukaemia treated with the MASPORE 2006 protocol | |
Cooperative regulation of coupled oncoprotein translation and stability in triple-negative breast cancer by EGFR and CDK12 | |
Protocol for the diagnostic performance of C-reactive protein, procalcitonin and interleukin-6 for serious bacterial infections among children ≤ 36 months old presenting with fever without source | |
Alterations in drug pharmacokinetics in critically ill children supported on extracorporeal membrane oxygenation: A systematic review | |
An intronic FTO variant rs16952570 confers protection against thiopurine-induced myelotoxicities in multiethnic Asian IBD patients | |
Pharmacokinetics alterations in critically ill paediatric patients on extracorporeal membrane oxygenation: A systematic review | |
Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients | |
EGFR mutation subtypes influence survival outcomes following first-line gefitinib therapy in advanced Asian NSCLC patients | |
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients | |
Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients | |
A phase I pharmacokinetic study of metronomic vinorelbine and sorafenib using two schedules in Asian NSCLC patients | |
Therapeutic drug monitoring of thiopurines in the management of Asian patients with inflammatory bowel disease | |
Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules | |
Effects of oxaliplatin, capecitabine and irinotecan (OXIRI) on pancreatic ductal adenocarcinoma cell lines carrying different Kras mutational status | |
Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients | |
Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukaemia & gastrointestinal stromal tumour patients | |
Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and their influence on tamoxifen disposition in Asian breast cancer patients | |
Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: A comparative review | |
Evaluation of severe neutropenia and diarrhoea in Asian cancer patients receiving UGT1A1 genotype-guided irinotecan dosing | |
Influence of EGFR exon 19 mutation subtypes on survival outcomes in advanced stage Asian non-small cell lung cancer patients receiving TKI therapy | |
Pharmacogenetics and its relevance to clinical practice |
Healthcare for the Whole Family
Our team includes both male and female doctors, ensuring a welcoming and comfortable experience for couples and families seeking care.
Personalised healthcare grounded in evidence and empathy
